Neurofibroma differential diagnosis

Jump to navigation Jump to search

Neurofibroma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Neurofibroma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

Staging

History and Symptoms

Physical Examination

Laboratory Findings

X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Neurofibroma differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Neurofibroma differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Neurofibroma differential diagnosis

CDC on Neurofibroma differential diagnosis

Neurofibroma differential diagnosis in the news

Blogs on Neurofibroma differential diagnosis

Directions to Hospitals Treating Neurofibroma

Risk calculators and risk factors for Neurofibroma differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sara Mohsin, M.D.[2] Shanshan Cen, M.D. [3]

Overview

Neurofibroma must be differentiated from schwannoma, dermatofibrosarcoma protuberans (DFSP), ganglioneuroma, and melanocytic nevus.

Differential Diagnosis

Neurofibroma must be differentiated from:[1][2]

  • Schwannoma
  • Dermatofibrosarcoma protuberans (DFSP)
  • Ganglioneuroma
  • Melanocytic nevus
  • Myxoid liposarcoma
  • Solitary circumscribed neuroma (palisaded encapsulated neuroma)
  • Traumatic neuroma
  • Neurotized nevus
  • Superficial angiomyxoma
  • Nerve sheath myxoma
  • Malignant peripheral nerve sheath tumor (MPNST): has marked atypia and increased mitotic activity, may have necrosis
  • Spindle cell lipoma
  • Leiomyoma: has cigar-shaped nuclei, S100 negative, positive for smooth muscle actin and desmin
  • Inflammatory myofibroblastic tumor: reactive spindle cells in inflammatory background
Differentiating neurofibroma from other diseases
Disease entity Etiology (Genetic or other) Histopathological findings Immunohistochemical staining Benign/Malignant Risk factors Common site of involvement Clinical manifestations Other associated features
Neurofibroma
  • Uniphasic, low to moderate cellularity
  • Non-encapsulated
  • Random pattern, only rare palisading
  • No well formed verocy bodies
  • Cells separated by collagen bundles
  • Hypocellular with abundant mucinous matrix
  • No peripheral perineural capsule
  • Frequent mast cells
  • Contains neural fibroblasts and fibrillary collagen
  • Random proliferation of Schwann cells and scattered admixed axons
  • No nevoid cells
  • No epithelial component
  • Diffuse growth pattern
  • Scant cytoplasm
  • Wavy cells with buckled nuclei
  • Pseudomeissnerian bodies representing specific differentiation may be present
  • Lacks storiform pattern

Neurofibroma with degenerative atypia ("ancient change") has following microscopic features:

  • Localized cells with large pleomorphic nuclei, cytoplasmic nuclear inclusions, smudgy chromatin, and inconspicuous nuclei
  • Absent or very low mitotic activity
  • Low to moderate cellularity
Positive for:
  • S100
  • Sox10
  • Neurofilament (and Bielshowsky)
  • GFAP
  • CD34
  • Factor XIIIa
  • Calretinin (focal)
  • NF-1 associated
  • Can occur anywhere
  • Nerve often not identified, incorporates nerve, axons often present in lesion
  • Seldom cystic
  • Frequently multiple
  • Widespread soft tissue infiltration
  • Tends to displace adnexa
  • <2cm in diameter
  • Lacks distinct lobulation
  • Lacks fat
Schwannoma
  • Encapsulated
  • Biphasic (majority entirely hypercellular Antoni A & hypocellular Antoni B)
  • Palisading
  • Verocay bodies
  • Infrequent extracellular collagen
Positive for:
  • S-100
  • Sox10
  • CD34
  • Neurofilament (and Bielshowsky)
  • Factor XIIIa (focal)
  • Calretinin
  • GFAP
  • NF-2 associated
  • Nerve often identifiable
  • Eccentric to nerve, axons generally absent within lesion
  • Occasionally cystic
Palisaded encapsulated neuroma
  • Solitary
  • Moderately cellular lesion
  • Rare mast cells
  • Predominantly composed of mast cells
Positive for:
  • EMA

Negative for:

  • GFAP
  • 90% lesions affect the face
  • No known familial association
Traumatic neuroma
Neurotized Melanocytic Nevus
Cutaneous Myxoma (Superficial angiomyxoma)
Nerve sheath myxoma
Malignant peripheral nerve sheath tumor
Dermatofibrosarcoma protuberans (DFSP)
Spindle cell lipoma

References


Template:WikiDoc Sources